Hemo China
PrivateLast Round
Series C
Jan 5, 2021
Est. Valuation
$456.4M
Total Funding Raised
$138.5M
Company Overview
Hemo China operates in Healthcare & Life Sciences and is based in Beijing. Its latest recorded funding round was a Series C round in January 2021.
Hemo China is a medical device company that develops and manufactures innovative interventional solutions for cerebrovascular and peripheral vascular diseases.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hemo China Comparables
Compare Hemo China with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NeuroSafe Medical Co., Ltd. | 88% | |
| Skynor Medical | 87% | |
| Wallaby Medical | 84% |
For institutional investors. Book with your work email.
Hemo China Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jan 5, 2021 | ||||
| Series B | Oct 10, 2020 | ||||
| Series A Extension | Apr 25, 2020 | ||||
| Series A | Sep 22, 2017 |
For institutional investors. Book with your work email.
Hemo China Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 3H Health Investment | Series C, Series B |
| OrbiMed | Series C |
| Legend Capital | Series B |
| Trustbridge Partners | Series C |
| Hudson Bay Capital Management | Series C |
| Lilly Asia Ventures | Series C |
| Octagon Capital | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 25, 2020
$12M round raised at $98M post-money valuation.
- Sep 22, 2017
Raised $27M in Series A funding.
For institutional investors. Book with your work email.
Hemo China Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Hemo China's valuation, stock price, and market status.
Is Hemo China a public or private company?
Hemo China is a private company.
What is the current stock price of Hemo China?
Hemo China is a private company, so its shares have no public market price. Caplight tracks Hemo China's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Hemo China worth (valuation)?
Hemo China's valuation is estimated at $456.4M based on funding round data.
Can I buy Hemo China stock?
Hemo China shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Hemo China's last funding round?
Hemo China's most recent funding round was Series C on January 5, 2021.
Who are the main investors in Hemo China?
Key investors in Hemo China include OrbiMed, Lilly Asia Ventures.
Will Hemo China IPO soon?
No public IPO plans have been announced for Hemo China.
How can I track Hemo China secondary market activity?
Caplight tracks bids, offers, and trades in Hemo China's shares on secondary markets.